K J Somaiya Super Speciality Hospital & Research Centre Trials

K J Somaiya Super Speciality Hospital & Research Centre	Welcome, Profile Billing Logout

62 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Ross, Cecil

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Podolak-Dawidziak, Maria

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

PEYVANDI, Flora

NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting

Europe, US, RoW

von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Von Willebrand Disease

01/25

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting

Europe, US, RoW

TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930

Takeda, Takeda Development Center Americas, Inc.

Thrombotic Thrombocytopenic Purpura (TTP)

03/25

PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Terminated

Europe, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia B with Inhibitor, Hemophilia B

11/24

02/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

LOVMIC, NCT05116501: Genetic Background of Patients With Low Von Willebrand Factor Levels

Recruiting

N/A

300

Europe

Whole-exome sequencing

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Low Von Willebrand Factor

10/22

05/23

NCT06376786: Italian iTTP Registry

Recruiting

N/A

132

Europe

Fondazione Luigi Villa

TTP - Thrombotic Thrombocytopenic Purpura

05/30

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

HISTORY, NCT03797495 / 2012-004442-15: Study of Individuals Affected With Hypoplasminogenemia

Recruiting

N/A

100

Europe, Canada, US, RoW

Indiana Hemophilia &Thrombosis Center, Inc., Fondazione Angelo Bianchi Bonomi

Plasminogen Deficiency

03/27

04/27

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

Rangarajan, Savita

NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed

RoW

ADVATE

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Hemophilia A

02/23

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Klamroth, Robert

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

ITP-Registry, NCT05152238: ITP Registry and Accompanying Biospecimen Collection

Recruiting

N/A

1100

Europe

Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx

Immune Thrombocytopenia

09/26

04/27

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients

Recruiting

N/A

200

Europe, Canada, US, RoW

Octapharma

Haemophilia a

06/30

Malan, Daniel R

Sisonke Boost, NCT05148845: Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Recruiting

500000

RoW

Booster vaccine

Wits Health Consortium (Pty) Ltd, National Department of Health of South Africa, National Institute of Communicable Diseases - NICD, KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP, Fred Hutchinson Cancer Center, Hutchinson Center Research Institute of South Africa (HCRISA), Janssen Vaccines & Prevention B.V., Bio Analytical Research Corporation, Dis-Chem Pharmacy, BioVac, Biocair, Right to Care, Clinical Laboratory Services, Institute of Infectious Disease and Molecular Medicine

SARS CoV 2 Infection

01/22

06/23

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Korczowski, Bartosz

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting

120

Europe, Canada, Japan, US, RoW

Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002

Takeda, Takeda Development Center Americas, Inc.

Crohn's Disease (CD)

11/24

VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting

778

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Crohn's Disease

11/24

12/26

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

Galapeduca, NCT06865417: A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Not yet recruiting

Europe, RoW

Filgotinib

Alfasigma S.p.A.

Ulcerative Colitis

06/27

06/28

NCT04701411 / 2020-003193-48: A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

Active, not recruiting

Europe, Japan, RoW

Darvadstrocel, Cx601

Takeda, Takeda Development Center Americas, Inc.

Crohn's Disease, Complex Perianal Fistula

12/25

MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting

121

Europe, Canada, Japan, US, RoW

Vedolizumab, MLN0002, ENTYVIO, KYNTELES

Takeda, Takeda Development Center Americas, Inc.

Colitis, Ulcerative

08/25

SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting

Europe, Canada, Japan, US, RoW

Mirikizumab IV, LY3074828, Mirikizumab SC

Eli Lilly and Company

Ulcerative Colitis

07/26

03/27

NCT06100289: A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Recruiting

Europe, Japan, US, RoW

Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002, Vedolizumab SC, MLN0002SC

Takeda

Ulcerative Colitis, Crohn's Disease

06/27

AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company, Eli Lilly and Company

Crohn's Disease

07/27

10/27

SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting

150

Europe, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company, Eli Lilly and Company

Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease

07/30

NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting

240

Europe, Canada, Japan, US, RoW

Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention

Takeda, Takeda Development Center Americas, Inc.

Ulcerative Colitis, Crohn's Disease

08/31

NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting

268

Europe, Canada, Japan, US, RoW

TAK-279, Zasocitinib, Placebo

Takeda

Crohn's Disease

09/26

07/27

NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting

207

Europe, Canada, Japan, US, RoW

TAK-279, Zasocitinib, Placebo

Takeda

Ulcerative Colitis

09/26

08/27

ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting

212

Europe, US, RoW

Obefazimod, Placebo

Abivax S.A.

Moderately to Severely Active Crohn Disease

12/26

04/28

NCT02616302 / 2014-004506-15: A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Recruiting

Europe, Canada, US, RoW

Dexlansoprazole, Dexilant

Takeda

Gastroesophageal Reflux Disease (GERD)

10/27

NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed

153

Europe, Canada, US

TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar

Takeda

Celiac Disease

11/24

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

NCT02615184 / 2014-004507-73: A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

Recruiting

Europe, Canada, US, RoW

Dexlansoprazole, Dexilant

Takeda

Erosive Esophagitis

10/27

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

John, Joseph

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

NCT06152679: Day-case Endourology; Patient Experience

Recruiting

N/A

Europe

None - qualitative interviews

Royal Devon and Exeter NHS Foundation Trust, Royal Cornwall Hospitals Trust, North Bristol NHS Trust, Gloucestershire Hospitals NHS Foundation Trust, King's College Hospital NHS Trust, Portsmouth Hospitals NHS Trust

Bladder Cancer, Bladder Outflow Obstruction

04/24

10/24

NCT06152666: Day-case Endourology; Enablers, Barriers, Unexpected Outcomes

Recruiting

N/A

Europe

None - qualitative interviews

Bladder Cancer, Bladder Outlet Obstruction, Urolithiasis

04/24

10/24

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Trautmann-Grill, Karolin

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Jul 2024 - Dec 2024 : Data for RRMM

Active, not recruiting

177

Europe, Canada, US, RoW

Belantamab mafodotin

GlaxoSmithKline

Multiple Myeloma

08/24

01/26

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

ITP-Registry, NCT05152238: ITP Registry and Accompanying Biospecimen Collection

Recruiting

N/A

1100

Europe

Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx

Immune Thrombocytopenia

09/26

04/27

Laguna, Pawel

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Kshirsagar, Shrinath

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Terminated

Europe, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia B with Inhibitor, Hemophilia B

11/24

02/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Ross, Cecil

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Podolak-Dawidziak, Maria

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

PEYVANDI, Flora

NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting

Europe, US, RoW

von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Von Willebrand Disease

01/25

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting

Europe, US, RoW

TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930

Takeda, Takeda Development Center Americas, Inc.

Thrombotic Thrombocytopenic Purpura (TTP)

03/25

PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Terminated

Europe, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia B with Inhibitor, Hemophilia B

11/24

02/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

LOVMIC, NCT05116501: Genetic Background of Patients With Low Von Willebrand Factor Levels

Recruiting

N/A

300

Europe

Whole-exome sequencing

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Low Von Willebrand Factor

10/22

05/23

NCT06376786: Italian iTTP Registry

Recruiting

N/A

132

Europe

Fondazione Luigi Villa

TTP - Thrombotic Thrombocytopenic Purpura

05/30

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

HISTORY, NCT03797495 / 2012-004442-15: Study of Individuals Affected With Hypoplasminogenemia

Recruiting

N/A

100

Europe, Canada, US, RoW

Indiana Hemophilia &Thrombosis Center, Inc., Fondazione Angelo Bianchi Bonomi

Plasminogen Deficiency

03/27

04/27

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

Rangarajan, Savita

NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed

RoW

ADVATE

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Hemophilia A

02/23

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Klamroth, Robert

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

ITP-Registry, NCT05152238: ITP Registry and Accompanying Biospecimen Collection

Recruiting

N/A

1100

Europe

Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx

Immune Thrombocytopenia

09/26

04/27

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients

Recruiting

N/A

200

Europe, Canada, US, RoW

Octapharma

Haemophilia a

06/30

Malan, Daniel R

Sisonke Boost, NCT05148845: Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Recruiting

500000

RoW

Booster vaccine

SARS CoV 2 Infection

01/22

06/23

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Korczowski, Bartosz

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting

120

Europe, Canada, Japan, US, RoW

Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002

Takeda, Takeda Development Center Americas, Inc.

Crohn's Disease (CD)

11/24

VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting

778

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Crohn's Disease

11/24

12/26

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

Galapeduca, NCT06865417: A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Not yet recruiting

Europe, RoW

Filgotinib

Alfasigma S.p.A.

Ulcerative Colitis

06/27

06/28

NCT04701411 / 2020-003193-48: A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

Active, not recruiting

Europe, Japan, RoW

Darvadstrocel, Cx601

Takeda, Takeda Development Center Americas, Inc.

Crohn's Disease, Complex Perianal Fistula

12/25

MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting

121

Europe, Canada, Japan, US, RoW

Vedolizumab, MLN0002, ENTYVIO, KYNTELES

Takeda, Takeda Development Center Americas, Inc.

Colitis, Ulcerative

08/25

SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting

Europe, Canada, Japan, US, RoW

Mirikizumab IV, LY3074828, Mirikizumab SC

Eli Lilly and Company

Ulcerative Colitis

07/26

03/27

NCT06100289: A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Recruiting

Europe, Japan, US, RoW

Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002, Vedolizumab SC, MLN0002SC

Takeda

Ulcerative Colitis, Crohn's Disease

06/27

AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company, Eli Lilly and Company

Crohn's Disease

07/27

10/27

SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting

150

Europe, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company, Eli Lilly and Company

Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease

07/30

NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting

240

Europe, Canada, Japan, US, RoW

Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention

Takeda, Takeda Development Center Americas, Inc.

Ulcerative Colitis, Crohn's Disease

08/31

NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting

268

Europe, Canada, Japan, US, RoW

TAK-279, Zasocitinib, Placebo

Takeda

Crohn's Disease

09/26

07/27

NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting

207

Europe, Canada, Japan, US, RoW

TAK-279, Zasocitinib, Placebo

Takeda

Ulcerative Colitis

09/26

08/27

ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting

212

Europe, US, RoW

Obefazimod, Placebo

Abivax S.A.

Moderately to Severely Active Crohn Disease

12/26

04/28

NCT02616302 / 2014-004506-15: A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Recruiting

Europe, Canada, US, RoW

Dexlansoprazole, Dexilant

Takeda

Gastroesophageal Reflux Disease (GERD)

10/27

NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed

153

Europe, Canada, US

TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar

Takeda

Celiac Disease

11/24

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

NCT02615184 / 2014-004507-73: A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

Recruiting

Europe, Canada, US, RoW

Dexlansoprazole, Dexilant

Takeda

Erosive Esophagitis

10/27

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

John, Joseph

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

NCT06152679: Day-case Endourology; Patient Experience

Recruiting

N/A

Europe

None - qualitative interviews

Bladder Cancer, Bladder Outflow Obstruction

04/24

10/24

NCT06152666: Day-case Endourology; Enablers, Barriers, Unexpected Outcomes

Recruiting

N/A

Europe

None - qualitative interviews

Bladder Cancer, Bladder Outlet Obstruction, Urolithiasis

04/24

10/24

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Trautmann-Grill, Karolin

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Jul 2024 - Dec 2024 : Data for RRMM

Active, not recruiting

177

Europe, Canada, US, RoW

Belantamab mafodotin

GlaxoSmithKline

Multiple Myeloma

08/24

01/26

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

ITP-Registry, NCT05152238: ITP Registry and Accompanying Biospecimen Collection

Recruiting

N/A

1100

Europe

Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx

Immune Thrombocytopenia

09/26

04/27

Laguna, Pawel

PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated

N/A

108

Europe, Canada, US, RoW

No Intervention

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

Kshirsagar, Shrinath

PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated

RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

01/25

PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Terminated

Europe, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia B with Inhibitor, Hemophilia B

11/24

02/25

PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated

Europe, Canada, US, RoW

SerpinPC, Activated Protein C (APC) inhibitor

ApcinteX Ltd, Centessa Pharmaceuticals plc

Hemophilia a, Hemophilia B

11/24

02/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites